Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack survivors get a secret weapon: a mini monitor that spots hidden danger

NCT ID NCT05073419

Knowledge-focused Sponsor: Samir Saba Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

After a heart attack, patients face a high risk of dangerous heart rhythms, but current monitoring methods may miss them. This trial tests whether a small implantable cardiac monitor (ICM) placed under the skin can catch these rhythms earlier and help doctors adjust treatment. Two hundred adults who recently had a heart attack will either receive the ICM or standard follow-up care. The goal is to see if the device leads to more timely and effective treatment changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Implantable cardiac monitor (ICM)
What this could lead to
If successful, this could show that routine monitoring with an ICM helps doctors detect and treat heart rhythm problems earlier after a heart attack, potentially improving survival.
What could go wrong
This is a small, early-phase study (200 participants) focused on detecting arrhythmias, not on proving survival benefit. The monitor may find harmless rhythms that lead to unnecessary procedures, or it may not change outcomes at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults, age 18 years or older * AMI (STEMI and NSTEMI) * Willing to give written informed consent * Expected discharge from hospital within 7 days of AMI * Willing to receive ICM insertion within 21 days of index AMI Exclusion Criteria: * Existing pacemaker, ICD, ICM, or any other implantable cardiac electronic device * Pregnant * Index AMI was more than 21 days * Unwilling/cannot insert ICM within 21 days post AMI * Planned ICD implant, planned CABG or any open-heart surgery (e.g. for severe valvular disease)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myocardial infarction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UPMC Presbyterian Hospital

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.